Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment

• Published in: Clinical pharmacokinetics Vol. 56; no. 2; pp. 153 - 163
• Main Authors: Khatri, Amit, Dutta, Sandeep, Marbury, Thomas C., Preston, Richard A., Rodrigues, Lino, Wang, Haoyu, Awni, Walid M., Menon, Rajeev M.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.02.2017; Springer Nature B.V
• Subjects: Aged; Anilides - administration & dosage; Anilides - adverse effects; Anilides - pharmacokinetics; Antiretroviral drugs; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - pharmacokinetics; Antiviral drugs; Carbamates - administration & dosage; Carbamates - adverse effects; Carbamates - pharmacokinetics; Comorbidity; Drug dosages; Drug Therapy, Combination; Family medical history; Female; Hepacivirus - drug effects; Hepacivirus - metabolism; Hepatitis; Hepatitis C; Hepatitis C, Chronic - blood; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - epidemiology; Humans; Infections; Interferon; Internal Medicine; Kidney diseases; Kidney Diseases - blood; Kidney Diseases - drug therapy; Kidney Diseases - epidemiology; Liver; Macrocyclic Compounds - administration & dosage; Macrocyclic Compounds - adverse effects; Macrocyclic Compounds - pharmacokinetics; Male; Medicine; Medicine & Public Health; Middle Aged; Original Research Article; Pharmaceuticals; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Proteins; Ritonavir - administration & dosage; Ritonavir - adverse effects; Ritonavir - pharmacokinetics; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - pharmacokinetics; Survival analysis; Treatment Outcome; Uracil - administration & dosage; Uracil - adverse effects; Uracil - analogs & derivatives; Uracil - pharmacokinetics; Normal Renal Function; Severe Renal Impairment; Renal Impairment; Telaprevir; Ritonavir

Background The direct-acting antiviral agent (DAA) combination of ombitasvir and paritaprevir (administered with ritonavir) with (3D regimen) or without (2D regimen) dasabuvir has shown very high efficacy rates in the treatment of chronic hepatitis C virus (HCV) infection. Renal impairment, a common...